Previous 10 | Next 10 |
AXU, MRNS, PDD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Marinus has a March PDUFA date - when the FDA will rule on whether to approve an oral formulation of Ganaxolone in CDKL5 Deficiency Disorder ("CDD"). Ganaxolone is Marinus' lead and only product and it has a long and checkered history - having failed in depression, it may succeed in e...
Marinus (MRNS -20.5%) has recorded the biggest intraday loss since March 2020 on Wednesday to approach a 52-week low after the clinical-stage pharma company announced delays for several clinical programs involving an IV formulation of its only product candidate, ganaxolone. The company a...
Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...
The clinical stage pharmaceutical company, Marinus Pharma (NASDAQ:MRNS) has lost ~18% in the post market Tuesday after Radnor, Pennsylvania-based firm announced delays to several clinical studies citing the impact of COVID-19 and Omicron variant of the virus. In addition to Omicron ...
RAISE trial delayed due to impacts from COVID-19 variant and recent interruption in clinical supply material Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today a...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ende...
In vivo study of M2 metabolite shows no signs of genotoxicity Marinus’ CDKL5 deficiency disorder marketing authorization application to convert to standard review timeline Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that company management will present virtually during the H.C. Wainwright Bioconnect Conference as well as t...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...